Abstract:Im stetig wachsenden Feld der Polymer‐basierten Wirkstoff‐Transport‐Systeme gilt Poly(ethylenglycol) (PEG) als der Goldstandard für Stealth‐Polymere. Welche Eigenschaften PEG aufweist, die diese herausragende Stellung rechtfertigen, soll in diesem Aufsatz diskutiert werden. Die ersten PEGylierten Produkte erschienen bereits vor 20 Jahren auf dem Markt. Seither konnten viele Erkenntnisse in klinischen Untersuchungen gewonnen werden, allerdings wurden dabei nicht nur Vorteile festgestellt, sondern auch mögliche … Show more
“…[21][22][23][24][25][26] To date, PEG, also referred to as poly(ethylene oxide) (PEO) for molecular weights above 20 000 g mol À1 , is the established reference polymer for pharmaceutical and biomedical applications, because of 1) its excellent solubility in both aqueous and organic media, 2) the fact that it displays no immunogenicity, antigenicity, or toxicity and 2) the high flexibility and hydration of the main chain. [27][28][29][30] Often PEG is…”
In the rapidly evolving multidisciplinary field of polymer therapeutics, tailored polymer structures represent the key constituent to explore and harvest the potential of bioactive macromolecular hybrid structures. In light of the recent developments for anticancer drug conjugates, multifunctional polymers are becoming ever more relevant as drug carriers. However, the potentially best suited polymer, poly(ethylene glycol) (PEG), is unfavorable owing to its limited functionality. Therefore, multifunctional linear copolymers (mf-PEGs) based on ethylene oxide (EO) and appropriate epoxide comonomers are attracting increased attention. Precisely engineered via living anionic polymerization and defined with state-of-the-art characterization techniques-for example real-time (1)H NMR spectroscopy monitoring of the EO polymerization kinetics-this emerging class of polymers embodies a powerful platform for bio- and drug conjugation.
“…[21][22][23][24][25][26] To date, PEG, also referred to as poly(ethylene oxide) (PEO) for molecular weights above 20 000 g mol À1 , is the established reference polymer for pharmaceutical and biomedical applications, because of 1) its excellent solubility in both aqueous and organic media, 2) the fact that it displays no immunogenicity, antigenicity, or toxicity and 2) the high flexibility and hydration of the main chain. [27][28][29][30] Often PEG is…”
In the rapidly evolving multidisciplinary field of polymer therapeutics, tailored polymer structures represent the key constituent to explore and harvest the potential of bioactive macromolecular hybrid structures. In light of the recent developments for anticancer drug conjugates, multifunctional polymers are becoming ever more relevant as drug carriers. However, the potentially best suited polymer, poly(ethylene glycol) (PEG), is unfavorable owing to its limited functionality. Therefore, multifunctional linear copolymers (mf-PEGs) based on ethylene oxide (EO) and appropriate epoxide comonomers are attracting increased attention. Precisely engineered via living anionic polymerization and defined with state-of-the-art characterization techniques-for example real-time (1)H NMR spectroscopy monitoring of the EO polymerization kinetics-this emerging class of polymers embodies a powerful platform for bio- and drug conjugation.
“…Similar results were obtained by Salvati et al, where transferrin-targeted silica nanoparticles also experienced a reduction in binding specificity after exposure to serum. [11] Once we had confirmed that serum protein effectively reduced the targeting specificity of Herceptin-conjugated nanoparticles towards ErbB2+ cells, we determined whether Figure 1. Binding specificity is reduced by serum-protein adsorption but this effect is alleviated by PEG backfilling.…”
mentioning
confidence: 98%
“…[10] To suppress protein adsorption, researchers often functionalize the nanoparticle surface with the antifouling polymer polyethylene glycol (PEG). [11] In order to properly design target-specific nanoparticles, a detailed understanding of the amount of PEG to apply and type of PEG to use is essential to effectively reduce serum-protein-nanoparticle interactions.…”
Always cite the published version, so the author(s) will receive recognition through services that track citation counts, e.g. Scopus. If you need to cite the page number of the TSpace version (original manuscript or accepted manuscript) because you cannot access the published version, then cite the TSpace version in addition to the published version using the permanent URI (handle) found on the record page.
“…[6] Unfortunately,m ost available stimuli-responsive systems have alimited chance of reaching clinical trial owing to the complexity of architectural design, difficulties in the scaling up,and potential toxicity concerns. [7] At ypical polymeric and nano-therapeutic based on these polymers is Genexol-PM, which is approved in South Korea and is undergoing clinical investigation in the United States. [7] At ypical polymeric and nano-therapeutic based on these polymers is Genexol-PM, which is approved in South Korea and is undergoing clinical investigation in the United States.…”
Successful bench-to-bedside translation of nanomedicine relies heavily on the development of nanocarriers with superior therapeutic efficacy and high biocompatibility. However, the optimal strategy for improving one aspect often conflicts with the other. Herein, we report a tactic of designing tumor-pH-labile linkage-bridged copolymers of clinically validated poly(D,L-lactide) and poly(ethylene glycol) (PEG-Dlink(m)-PDLLA) for safe and effective drug delivery. Upon arriving at the tumor site, PEG-Dlink(m)-PDLLA nanoparticles will lose the PEG layer and increase zeta potential by responding to tumor acidity, which significantly enhances cellular uptake and improves the in vivo tumor inhibition rate to 78.1% in comparison to 47.8% of the non-responsive control. Furthermore, PEG-Dlink(m)-PDLLA nanoparticles show comparable biocompatibility with the clinically used PEG-b-PDLLA micelle. The improved therapeutic efficacy and safety demonstrate great promise for our strategy in future translational studies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.